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Abstract 
Synthetic oligosaccharides composed of several repeats of Shigella dysenteriae type 1 O-specific 
polysaccharide (O-SP), bound by their reducing ends to a carrier protein (“sun” type configuration), 
induced in mice significantly higher antibody levels than conjugates of the native O-SP (”lattice” type 
configuration). Here we present isolation and characterization of low molecular mass oligosaccharides of 
Shigella sonnei lipopolysaccharides and their conjugation to several carrier proteins. Conjugates were 
formed by oxime linkages between the terminal Kdo residues of the reducing ends of the saccharides and 
aminooxy linkers bound to the protein. IgG antibody levels induced in young outbread mice by these 
conjugates were significantly higher than those prepared with the full length native O-SP. We propose 
clinical evaluation of the new S. sonnei conjugates. 
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Shigellae cause endemic and epidemic diarrhea and/or dysentery worldwide, especially in 
developing countries. At least one half the cases and deaths occur in children less than 5 years old. Despite 
its discovery over a century ago, there is still no licensed vaccine for shigellae. Residual morbidity, even 
after effective antibiotic therapy, and increasing antibiotic resistance of shigellae urge the development of 
vaccines to prevent disease caused by this pathogen.  
Lipopolysaccharides (LPS) of Shigella are essential virulence factors. An LPS-based vaccine 
elicited 74 % protection against shigellosis in Israeli Army recruits at 8-14% infection rates [1]. The 
efficacy was related to vaccine induced IgG anti-O-SP levels. Evaluation of such conjugates in children, 
having highest incidence and severity of S. sonnei shigellosis, showed an age related antibody responses 
and protection.  
A significant improvement in the immunogenicity of S. dysenteriae type 1 conjugates was 
achieved using short synthetic fragments of O-SP bound by their reducing ends to a protein carrier [2]. 
However the synthesis of S. sonnei O-SP oligosaccharides has not been possible to date. We used therefore 
low mass O-SP-core (O-SPC) fragments isolated from the LPS to bind to carrier proteins, similarly to the 
preparation of the synthetic S. dysenteriae type 1 oligosaccharide-protein conjugates. 
LPS from S. sonnei strain 53G was extracted by the hot phenol method and purified by 
ultracentrifugation. Next, LPS was hydrolyzed with 1% acetic acid at 100°C for 1.5 h, Lipid A removed by 
ultracentrifugation and the soluble product subjected to gel chromatography on a BioGel P-10 (1x100 cm) 
column in pyridine/acetic acid/water buffer (4/8/988 ml). Four fractions were obtained and analyzed by 
NMR and mass spectroscopy [1]. Integration of the O-SP FucNAc4N methyl signal in 1H-NMR spectra 
(1.34-1.36 ppm) relative to the anomeric signals of core α-Gal M (5.82 ppm) and α-Gal L (5.62 ppm) 
showed that fraction F1 contained core with approximately 29 O-SP repeat units (RU), F2: core with an 
average of 3.5 RU, and F3: core with an average of 1.3 RU. Fraction F4 contained various degradation 
products. Fraction F2 (O-SPC-F2) was analyzed in detail and the following structure was assigned: 
                                                                                            α-GlcN-7-α-Hep-7
                                                                                                                          |
                                                         α-Gal-2-α-Gal-2-α-Glc-3-α-Glc-3-α-Hep4P-3-α-Hep4P(PEtA)-5-Kdo
                                                                                             |            
               [-4-α-L-AltNAcA-3-β-FucNAc4N-]2-5-3-β-Glc-3 
                          
Four conjugates were prepared by binding O-SPC-F2 to either BSA (conj. 1; BSA/O-SPC-F2) or 
to recombinant diphtheria toxin (conj. 2, 3 and 4: rDT/O-SPC-F2). The conjugation was based on the 
formation of stable oxime linkages between the Kdo residue present at the O-SPC reducing-end and an 
aminooxy linker bound to the carrier protein [2, 3]. Conjugates were analyzed by MALDI-TOF mass 
spectrometry, SDS-PAGE and protein and sugar colorimetric assays; all methods provided comparable 
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of the carrier protein and of the O-SPC. Characterization of conjugates is presented in Table 1. All 
conjugates reacted by double immunodiffusion with rabbit anti-S. sonnei and anti-protein sera by an 
identity line. 
All conjugates elicited low levels of IgG anti-LPS after the 2nd injection with booster responses 
after the 3rd.  The geometric means (GM) of IgG anti-LPS are presented in Table 1. There were no 
statistical differences after the 3rd injection between conjugates 1, 2 and 4, which contained average 6-7 O-
SPC-F2 chains per protein molecule. Conjugate 3, which contained twice as much of O-SPC-F2 chains per 
rDT than the other conjugates, induced statistically lower antibody levels both to the saccharide and the 
protein. All four O-SPC-F2 conjugates induced statistically higher antibody levels then the ‘lattice’ type 
conjugate prepared with the full length O-SP.  
Table 1. Composition and GM of serum IgG anti-S. sonnei LPS induced by O-SPC-F2 conjugates  bound 
to bovine serum albumin (BSA) or to recombinant diphtheria toxin (rDT) and by full length O-SP 
bound to recombinant P. aeruginosa Exotoxin A (rEPA). 
   No. of O-SPC IgG [EU] IgG [EU1]  
No Conjugate Mm of  Mm of chains per anti-LPS anti-rDT    
 conjugate sugar part BSA or rDT 2nd 3rd 2nd 3rd
  [kDa] [kDa] molecule inj. inj. inj. inj. 
1 BSA/O-SPC-F22 93.1 22.2 7 79 366 nd3 nd 
2 rDT/O-SPC-F2 80.6 18.5 6 5 392 2 91 
3 rDT/O-SPC-F2 99.5 37.4 12 11 150 0.1 2 
4 rDT/O-SPC-F2 81.1 19.0 6 19 328 1 11 
5 rEPA/O-SP4 nd nd nd 11 67 nd nd 
1EU = ELISA Units; 2S. sonnei O-SPC-F2 = core + avr. 3.5 repeat units (RU) of O-SP; avr.molecular mass 
(Mm) = 3206 Da; 3nd = not determined;4S. sonnei O-SP = core + avr. 29 RU of O-SP bound by multi-point 
attachment 
Mice (10 per group) were injected with 2.5 μg of saccharide as a conjugate per mouse, 3 times, 2 weeks 
apart and bled one week after the last two injections.
Conclusion 
      Protein conjugates of the low molecular mass oligosaccharides containing LPS core plus 
average 2-5 O-SP repeat units (O-SPC) were prepared and characterized by physico-chemical and 
immunogenicity assays. These conjugates induced significantly higher IgG antibody levels then those 
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method is being studied with S. flexneri 2a, 6 and S. dysenteriae type 1 LPS. The mild reaction conditions 
and relative ease of preparation provided by O-SPC may be applicable for the preparation of conjugates 
against other Gram-negative pathogens such as non-typhoidal Salmonella or Escherichia coli O157.  
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